JP2023521411A5 - - Google Patents
Info
- Publication number
- JP2023521411A5 JP2023521411A5 JP2022562082A JP2022562082A JP2023521411A5 JP 2023521411 A5 JP2023521411 A5 JP 2023521411A5 JP 2022562082 A JP2022562082 A JP 2022562082A JP 2022562082 A JP2022562082 A JP 2022562082A JP 2023521411 A5 JP2023521411 A5 JP 2023521411A5
- Authority
- JP
- Japan
- Prior art keywords
- substantially shown
- ray diffraction
- infrared
- spectrum
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025260150A JP2026048873A (ja) | 2020-04-10 | 2025-12-17 | （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008161P | 2020-04-10 | 2020-04-10 | |
| US63/008,161 | 2020-04-10 | ||
| PCT/US2021/026663 WO2021207659A1 (en) | 2020-04-10 | 2021-04-09 | Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260150A Division JP2026048873A (ja) | 2020-04-10 | 2025-12-17 | （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521411A JP2023521411A (ja) | 2023-05-24 |
| JP2023521411A5 true JP2023521411A5 (https=) | 2024-04-18 |
Family
ID=75690727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562082A Pending JP2023521411A (ja) | 2020-04-10 | 2021-04-09 | （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体 |
| JP2025260150A Pending JP2026048873A (ja) | 2020-04-10 | 2025-12-17 | （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260150A Pending JP2026048873A (ja) | 2020-04-10 | 2025-12-17 | （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230151010A1 (https=) |
| EP (1) | EP4132930A1 (https=) |
| JP (2) | JP2023521411A (https=) |
| KR (1) | KR20230008742A (https=) |
| CN (1) | CN115916780A (https=) |
| AU (1) | AU2021253946A1 (https=) |
| BR (1) | BR112022020243A2 (https=) |
| CA (1) | CA3179957A1 (https=) |
| CL (1) | CL2022002786A1 (https=) |
| CO (1) | CO2022016067A2 (https=) |
| IL (1) | IL297206A (https=) |
| MX (1) | MX2022012523A (https=) |
| PE (1) | PE20231071A1 (https=) |
| WO (1) | WO2021207659A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71692A (fr) | 2022-08-01 | 2025-05-30 | Bristol-Myers Squibb Company | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
| KR20250136432A (ko) | 2023-02-06 | 2025-09-16 | 브리스톨-마이어스 스큅 컴퍼니 | 밀벡시안 제약 조성물 |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201908467RA (en) * | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
-
2021
- 2021-04-09 IL IL297206A patent/IL297206A/en unknown
- 2021-04-09 EP EP21722085.4A patent/EP4132930A1/en active Pending
- 2021-04-09 PE PE2022002222A patent/PE20231071A1/es unknown
- 2021-04-09 BR BR112022020243A patent/BR112022020243A2/pt unknown
- 2021-04-09 MX MX2022012523A patent/MX2022012523A/es unknown
- 2021-04-09 KR KR1020227039277A patent/KR20230008742A/ko active Pending
- 2021-04-09 CN CN202180039763.5A patent/CN115916780A/zh active Pending
- 2021-04-09 JP JP2022562082A patent/JP2023521411A/ja active Pending
- 2021-04-09 WO PCT/US2021/026663 patent/WO2021207659A1/en not_active Ceased
- 2021-04-09 AU AU2021253946A patent/AU2021253946A1/en active Pending
- 2021-04-09 CA CA3179957A patent/CA3179957A1/en active Pending
- 2021-04-09 US US17/995,848 patent/US20230151010A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002786A patent/CL2022002786A1/es unknown
- 2022-11-09 CO CONC2022/0016067A patent/CO2022016067A2/es unknown
-
2025
- 2025-12-17 JP JP2025260150A patent/JP2026048873A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521411A5 (https=) | ||
| JP2023519891A5 (https=) | ||
| JP4142621B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| JP2023554492A5 (https=) | ||
| JP2007532560A5 (https=) | ||
| JP2022534788A5 (https=) | ||
| JP2016528179A5 (https=) | ||
| CA2688709A1 (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| KR102142797B1 (ko) | 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도 | |
| JP2006137778A5 (https=) | ||
| JP2022533340A5 (https=) | ||
| JP2024530164A5 (https=) | ||
| JP2010514725A5 (https=) | ||
| JP2013520488A5 (https=) | ||
| JP2024505063A5 (https=) | ||
| JP2023530786A5 (https=) | ||
| JP2022525102A5 (https=) | ||
| US6521642B2 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis | |
| JP2024001040A5 (https=) | ||
| AU2001292907A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2024534268A5 (https=) | ||
| JP6818031B2 (ja) | モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途 | |
| CA3095922A1 (en) | Solid-state forms of abemaciclib, their use and preparation | |
| JP2018024683A5 (https=) |